ImmunityBio shares surge 10.80% after hours on FDA designations, positive trials, and 467% ANKTIVA sales growth.

ImmunityBio Inc. surged 10.80% in after-hours trading, driven by FDA designations, promising clinical trial results for glioblastoma and non-Hodgkin lymphoma, and a 467% year-to-date sales increase for its bladder cancer therapy ANKTIVA. Recent news highlighted growing patient preference for immunotherapy due to fewer side effects, bolstering investor confidence in the company’s market position. Strong financial results, including $75M in sales and ongoing trial advancements, further fueled optimism about future growth prospects.